Literature DB >> 11122250

Secretory autoantibodies in primary biliary cirrhosis (PBC).

J M Palmer1, M Doshi, J A Kirby, S J Yeaman, M F Bassendine, D E Jones.   

Abstract

It is unclear how breakdown in immune tolerance to the ubiquitous self-antigen pyruvate dehydrogenase complex (PDC), seen in the autoimmune liver disease PBC, gives rise to tissue damage with such a limited distribution (restricted to the liver and salivary and lachrymal glands). One property shared by these tissues is the ability to export secretory IgA by the process of transcytosis. The aim of this study was to address whether active transcytosis of anti-PDC IgA occurs across epithelial surfaces in PBC, a finding that might implicate mucosal specific immune mechanisms in the pathogenesis of this disease. Parotid saliva was collected from PBC patients (n = 44), normal controls (n = 28) and PBC patients post-liver transplantation (n = 11). IgA and secretory component-positive antibodies specific for human PDC were quantified by ELISA and immunoblotting. PBC patients (but not control subjects) had anti-PDC IgA in their saliva. The strong correlation seen between titres detected using anti-IgA and anti-secretory component antibodies suggests that this is predominantly secretory IgA reaching the saliva by the active process of epithelial transcytosis. Titres of anti-PDC IgA remain high in PBC patients saliva post-liver transplant. Findings from studies of IgA in viral infection models raise the possibility that anti-PDC IgA could, whilst undergoing transcytosis, bind to newly translated PDC components in the cytoplasm of the epithelial cells transporting them out of the cell and inducing metabolic damage. This model would, if correct, help to explain the mechanism and tropism of tissue damage in PBC and the aberrant pattern of expression of PDC on the apical surface of biliary and salivary epithelial cells reported in this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122250      PMCID: PMC1905785          DOI: 10.1046/j.1365-2249.2000.01403.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjögren's syndrome.

Authors:  A K Halse; M C Marthinussen; M Wahren-Herlenius; R Jonsson
Journal:  Scand J Rheumatol       Date:  2000       Impact factor: 3.641

2.  Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis.

Authors:  J Van de Water; L B Gerson; L D Ferrell; J R Lake; R L Coppel; K P Batts; R H Wiesner; M E Gershwin
Journal:  Hepatology       Date:  1996-11       Impact factor: 17.425

Review 3.  Primary biliary cirrhosis.

Authors:  J Neuberger
Journal:  Lancet       Date:  1997-09-20       Impact factor: 79.321

Review 4.  Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis.

Authors:  S J Yeaman; J A Kirby; D E Jones
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

5.  Glutamic acid decarboxylase autoantibodies in saliva of children with type 1 diabetes.

Authors:  A K Markopoulos; M A Belazi; D Drakoulakos
Journal:  Diabetes Res Clin Pract       Date:  1997-12       Impact factor: 5.602

6.  Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis.

Authors:  A Nishio; J Van de Water; P S Leung; R Joplin; J M Neuberger; J Lake; A Björkland; T H Tötterman; M Peters; H J Worman; A A Ansari; R L Coppel; M E Gershwin
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

7.  Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis.

Authors:  J M Palmer; D E Jones; J Quinn; A McHugh; S J Yeaman
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

8.  Salivary antigliadin and antiendomysium antibodies in coeliac disease.

Authors:  H Lähteenoja; A Toivanen; I Räihä; S Syrjänen; M Viander
Journal:  Scand J Immunol       Date:  1999-11       Impact factor: 3.487

Review 9.  Antimitochondrial antibodies in primary biliary cirrhosis.

Authors:  P S Leung; R L Coppel; A Ansari; S Munoz; M E Gershwin
Journal:  Semin Liver Dis       Date:  1997-02       Impact factor: 6.115

Review 10.  Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis.

Authors:  M F Bassendine; D E Jones; S J Yeaman
Journal:  Semin Liver Dis       Date:  1997-02       Impact factor: 6.115

View more
  6 in total

Review 1.  Pathogenesis of primary biliary cirrhosis.

Authors:  David E J Jones
Journal:  Gut       Date:  2007-07-19       Impact factor: 23.059

Review 2.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

3.  Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients.

Authors:  Ourania Sfakianaki; Meri Koulentaki; Maria Tzardi; Elena Tsangaridou; Panayotis A Theodoropoulos; Elias Castanas; Elias A Kouroumalis
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

Review 4.  The immunology of primary biliary cirrhosis: the end of the beginning?

Authors:  J M Palmer; J A Kirby; D E J Jones
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

5.  Autoantibodies to muscarinic acetylcholine receptors found in patients with primary biliary cirrhosis.

Authors:  Christoph P Berg; Karin Blume; Kirsten Lauber; Michael Gregor; Peter A Berg; Sebastian Wesselborg; Gerburg M Stein
Journal:  BMC Gastroenterol       Date:  2010-10-16       Impact factor: 3.067

6.  Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies.

Authors:  Isabell Nilsson; Jeremy Palmer; Eirini Apostolou; Carl-Gerhard Gottfries; Muhammad Rizwan; Charlotte Dahle; Anders Rosén
Journal:  Front Med (Lausanne)       Date:  2020-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.